PSMA (Prostate-Specific Membrane Antigen) is a protein with low expression in healthy prostate tissue but is dramatically upregulated in prostate cancer cells. This makes PSMA a great radiotracer for diagnostic, and in recent years, therapeutic purposes. In March 2022, FDA approved the use of Lu-PSMA (Pluvitco) for the treatment of adult PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). While this provides a viable alternative for patients, potential side effects from the toxicity of the radioactive ligand are a natural concern. In this webinar, we invite leaders in the field of prostate cancer care to share their insights and strategies in the administration of Lu-PSMA on patients in Singapore.
